Details for Patent: 9,000,021
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,000,021 protect, and when does it expire?
Patent 9,000,021 protects BENDEKA and is included in one NDA.
This patent has thirty-eight patent family members in fifteen countries.
Summary for Patent: 9,000,021
| Title: | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
| Abstract: | Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease. |
| Inventor(s): | Sundaram; Srikanth (Somerset, NJ), Tarriff; Scott L. (Mahwah, NJ) |
| Assignee: | Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ) |
| Application Number: | 13/838,267 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,000,021 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,000,021
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,000,021
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2867295 | See Plans and Pricing | |||
| Canada | 2867343 | See Plans and Pricing | |||
| China | 104271135 | See Plans and Pricing | |||
| China | 104302291 | See Plans and Pricing | |||
| China | 107157988 | See Plans and Pricing | |||
| Denmark | 2827863 | See Plans and Pricing | |||
| European Patent Office | 2827862 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
